Clinical trial
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental…
NCT00193648 · Northwell Health, Other · Completed
Key facts
| NCT number | NCT00193648 |
|---|---|
| Title | Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) |
| Official title | Novel Therapies for Resistant FSGS |
| Lead sponsor | Northwell Health, Other |
| Collaborators | University of North Carolina The Cleveland Clinic |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Focal Glomerulosclerosis |
| Intervention type | Drug |
| Interventions | Rosiglitazone (Avandia), Adalimumab (Humira) |
| Enrollment | 21 |
| Start date | Jul 1, 2005 |
| Completion | Oct 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 22, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: